Value creation in bio-energy Anton Robek Presiden - DSM

38 Pages·2012·3.34 MB·English

Value creation in bio-energy
Anton Robek
President DSM Bio-based Products & Services
Bio-based business seminar - December 4, 2012
London Stock Exchange
Safe harbor statement
This presentation may contain forward-looking statements with respect to DSM’s
future (financial) performance and position. Such statements are based on current
expectations, estimates and projections of DSM and information currently available to
the company. DSM cautions readers that such statements involve certain risks and
uncertainties that are difficult to predict and therefore it should be understood that
many factors can cause actual performance and position to differ materially from
these statements. DSM has no obligation to update the statements contained in this
presentation, unless required by law.
The English language version of this document is leading.
A more comprehensive discussion of the risk factors affecting DSM’s business can be
found in the company’s latest Annual Report, which can be found on the company's
corporate website, www.dsm.com
Slide 1
Overview
(cid:127) Introduction
(cid:127) Bio-energy
(cid:127) Value creation timeline
Slide 2
DSM has a broad range of bio-based platforms
Cell Fungi/ Advanced
Algae Enzymes Microbial
Culture Yeast Chemistry
In house bio-processes Biobased market positions Development
(cid:127) Fermentation processes (cid:127) Enzymes (cid:127) Advanced bioenergy
(cid:127) Anti-infectives (cid:127) Cultures (cid:127) Bio chemicals
(cid:127) Several vitamins (cid:127) Yeast extracts (cid:127) Renewable raw
(cid:127) Enzymes for Food, Feed
(cid:127) Pharma materials for polymers
(cid:127) Enzymes for Pharma
(cid:127) Biologics
(cid:127) Cultures
(cid:127) Biocatalysis
(cid:127) Vitamins
(cid:127) Semi-synthetic antibiotics
(cid:127) APIs and building blocks
(cid:127) Biopharmaceuticals
Slide 3
From technology to a total business model
DSM
Bio-Based Products
& Services
Bio-based chemicals
Bio-energy
& materials
synergy
(cid:127) Biosuccinium™ Succinic Acid
(cid:127) Cellulosic Bioethanol
(cid:127) Bio-based Adipic Acid
(cid:127) Renewable Diesel
(cid:127) Emerging Portfolio
(cid:127) Industrial Biogas
Slide 4
Building on proven biotechnology competences
CLASSICAL BIOTECH MODERN BIOTECH BIOECONOMY
(19th century) (20th century) (21st century)
(cid:127) MethaPlus (Biogas)
(cid:127) Yeast (cid:127) Food & Feed enzymes
(e.g. Phytase, Lactase, Proteases,... ) (cid:127) Advanced Cellulosic
(cid:127) Ethanol
(cid:127) Metabolic engineering Yeast & Enzymes
(cid:127) Yeast extracts
(e.g. Vitamin B2, Cephalexin, (cid:127) Renewable bio-diesel
(cid:127) Vitamins Arachidonic acid)
(cid:127) Biogas
(cid:127) Penicillin (cid:127) Biocatalysis
(cid:127) Platform chemicals:
(e.g. Pharma intermediates (PharmaPLE)
(cid:127) Enzymes
- Succinic acid
(cid:127) Cell culture
(cid:127) Citric acid - Adipic acid
(e.g. Per(cid:314)C6TM cell line)
(cid:127) Microbial oil platform
A unique track record of continuous innovation during 3 centuries
Slide 5
Biotechnology is a clear differentiator for DSM
(cid:127) > 150 years of biotechnology experience (Nederlandsche Gist- en Spiritusfabriek,
1869)
(cid:127) Clear biofuels focus from start of bio-based program:
– Cellulosic ethanol
– Enzymes & Yeast
– Fit for use in specific environment (pre-treatment, feedstock focus, …)
(cid:127) We know how to design, build & operate large scale installations
(cid:127) DSM has solid scientific track record
– 2011 R&D € 476m (5% of net sales), 2000 scientists
– In 2011, 262 scientific papers in
peer-reviewed journals
– Innovation Funnel & PMP process
– Intellectual Asset Management
(cid:127) 250+ patents filed per year
(cid:127) >100 professionals worldwide
Slide 6
(cid:127) Introduction
(cid:127) Bio-energy
(cid:127) Value creation timeline
Slide 7
Bio-energy at DSM: three exciting platforms
(cid:127) Cellulosic bio-ethanol
(cid:127) Renewable diesel
(cid:127) Bio-gas
Slide 8
Cellulosic bio-ethanol: very attractive opportunity
Market expectations
(cid:127) Global cellulosic bio-ethanol cellulosic bio-ethanol *
market expected to grow to 18bn (global demand in billion gallons)
20
gallons by 2022*
15
(cid:127) Resulting in market value for
US
enzymes & yeasts of ~ US$ 3-5bn by
10 China
2022
Brazil
5 EU
(cid:127) US is the largest market, followed
0
by China en Brazil
2011 2015 2020 2022
’
* derived from Hart’s Global Energy Study
Slide 9